Research programme: Parkinson's disease therapy - Titan Pharmaceuticals

Drug Profile

Research programme: Parkinson's disease therapy - Titan Pharmaceuticals

Alternative Names: Ropinirole implant - Titan Pharmaceuticals

Latest Information Update: 15 Nov 2016

Price : $50

At a glance

  • Originator Titan Pharmaceuticals
  • Class Ergolines
  • Mechanism of Action Dopamine D2 receptor agonists; Serotonin 1A receptor agonists; Serotonin 2A receptor antagonists; Serotonin 2B receptor antagonists; Serotonin 2C receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Dyskinesias; Parkinson's disease

Most Recent Events

  • 09 Nov 2016 Titan Pharmaceuticals plans to file IND application by January 2017
  • 13 May 2015 Titan Pharmaceuticals plans a phase I study for Parkinson's disease
  • 09 Jul 2012 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top